drugset / Trial / NCT07485595

A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression

NCT07485595

Phase 2/3 Not yet recruiting 180 enrolled Tasly Pharmaceutical Group Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression

Timeline

Start
2026-04-30
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject JS1-1-01 Unknown 75 mg
Subject JS1-1-01 Unknown 100 mg

Indications